Allworth Financial LP Buys 6,762 Shares of Abbott Laboratories $ABT

Allworth Financial LP raised its stake in Abbott Laboratories (NYSE:ABT) by 2.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 266,483 shares of the healthcare product maker’s stock after purchasing an additional 6,762 shares during the quarter. Allworth Financial LP’s holdings in Abbott Laboratories were worth $35,693,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. IFP Advisors Inc lifted its position in shares of Abbott Laboratories by 5.4% during the 3rd quarter. IFP Advisors Inc now owns 19,732 shares of the healthcare product maker’s stock worth $2,785,000 after buying an additional 1,011 shares in the last quarter. Steadtrust LLC grew its holdings in shares of Abbott Laboratories by 6.1% in the third quarter. Steadtrust LLC now owns 2,070 shares of the healthcare product maker’s stock valued at $277,000 after acquiring an additional 119 shares in the last quarter. Stillwater Wealth Management Group purchased a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $601,000. Tevis Investment Management lifted its holdings in Abbott Laboratories by 5.0% during the third quarter. Tevis Investment Management now owns 4,200 shares of the healthcare product maker’s stock worth $563,000 after acquiring an additional 200 shares during the period. Finally, Cambria Investment Management L.P. purchased a new position in Abbott Laboratories in the third quarter worth $700,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 2.1%

ABT stock opened at $108.41 on Thursday. The stock has a fifty day moving average of $113.54 and a 200-day moving average of $123.39. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.06. The company has a market capitalization of $188.81 billion, a price-to-earnings ratio of 29.14, a PEG ratio of 1.76 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of recent analyst reports. Oppenheimer reduced their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. The Goldman Sachs Group cut their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Barclays reduced their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Daiwa Securities Group lowered their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Finally, Evercore dropped their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $136.16.

Insider Buying and Selling

In related news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055 shares of company stock worth $353,097 in the last 90 days. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.